Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment. - Wikidata - awgldk - TriplyDB

Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment.

Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment.

http://www.wikidata.org/entity/Q34596658

about

New developments in the management of severe skin and deep skin structure infections - focus on tedizolid Tedizolid Phosphate: a Next-Generation Oxazolidinone.Pharmacokinetic drug evaluation of tedizolid for the treatment of skin infections.Tedizolid population pharmacokinetics, exposure response, and target attainment.Profile of tedizolid phosphate and its potential in the treatment of acute bacterial skin and skin structure infections Stability of Crushed Tedizolid Phosphate Tablets for Nasogastric Tube Administration.Newer antibiotics for the treatment of peritoneal dialysis-related peritonitis.Therapeutic options for vancomycin-resistant enterococcal bacteremia.Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens.Novel antibiotics: are we still in the pre-post-antibiotic era?Tedizolid for treatment of acute bacterial skin and skin structure infections.Mycobacterium abscessus Complex - a Particular Challenge in the Setting of Lung Transplantation.Drug monitoring and individual dose optimization of antimicrobial drugs: oxazolidinones.Critical role of tedizolid in the treatment of acute bacterial skin and skin structure infections Pharmacokinetics of Tedizolid in Obese and Nonobese Subjects.[New antibiotics prior to approval: is this the end of the innovative stagnation?].Tedizolid is highly bactericidal in the treatment of pulmonary Mycobacterium avium complex disease.Reduction in Tedizolid Plasma Exposure among End-Stage Renal Disease Patients Undergoing Dialysis Is Explained by Variations in Ideal Body Weight.Prolonged use of tedizolid in a pulmonary non-tuberculous mycobacterial infection after linezolid-induced toxicity.Dosing strategies to optimize currently available anti-MRSA treatment options (Part 2: PO options).Clinical Pharmacokinetics and Pharmacodynamics of Oxazolidinones.Pharmacokinetics of tedizolid in obese patient after bariatric surgery: a case report.Vancomycin-resistant enterococcus infection in the hematopoietic stem cell transplant recipient: an overview of epidemiology, management, and prevention.Pharmacokinetics, Safety, and Tolerability of Tedizolid Phosphate in Elderly Subjects.

P2860

Q28083116-B49838B2-967B-4D84-AB5C-AE144BBF1AA2 Q33420646-08742ADB-98F5-43D3-9A8A-93B883444F89 Q33438834-27373F40-6D5A-44EC-899C-5A5B6C554072 Q34596353-A77148D8-5F43-45FA-BA96-8EBFD22AB934 Q35542330-81A68F0A-8BA1-40CE-A1D0-71A0A551ABF0 Q36327804-F77C1C3D-2DAF-4FB7-B17F-6C4168682453 Q37119083-C3FC4CE0-1385-4399-95D6-3C3CCB240E7B Q38347869-40F4227E-8313-4881-977B-D964AB313B30 Q38352171-60CF2D62-9E50-42BF-9C94-6D1BB90B4D88 Q38363223-48C75413-CD03-4597-A37F-104C70B31EBB Q38554583-D2C1AB1C-386C-49B5-AD35-C59361092728 Q38687467-01A86730-9F51-4FAD-B67D-BEF2128DEC1C Q38777085-5E1D0117-B4D8-4464-A895-4A0CBC7BD726 Q39067666-EF9B640E-466B-4097-BF77-5F186F29950C Q40210571-D5DF474A-7ADA-4D5D-86A5-EAB1101880FF Q41675300-44AEB004-F6EB-434F-8D2D-8B5608D860C6 Q41996895-F96DEC90-F7B3-4C0B-96DB-3C522B177A1C Q42797201-52BF4A81-3673-4C5F-9B07-DF950C4AA12C Q43966214-0420B10D-DFD9-44C5-91A6-41E9F137486C Q47396324-05D6A6CB-934D-4D7A-9B83-EE519B4BE19D Q47611899-DD215776-5AD4-498E-8543-D05AA2E879AF Q47833934-BBBC57B0-BF25-486D-A2BF-D152BF695959 Q49446863-F0DD4D0F-C5F5-4E13-BFC0-0CC18D69D4B7 Q50104909-61800331-14C4-4A16-9BE7-72DCC4594579

P2860

Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment.

http://www.wikidata.org/entity/Q34596658

description

2014 nî lūn-bûn

@nan

2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

name

Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment.

@ast

Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment.

@en

Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment.

@nl

type

label

Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment.

@ast

Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment.

@en

Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment.

@nl

prefLabel

Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment.

@ast

Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment.

@en

Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment.

@nl

P1433

Q34596658-9F1BC01D-15AE-46AF-8DA2-14B4EF4980BE

P1476

Q34596658-09B8EF14-563C-4D01-95C5-8D3633AA7218

P2093

Q34596658-13ACEF90-72CA-42EE-B08A-49CCA3226284

Q34596658-2FFBACD8-B78F-4206-A545-54CB084C80F4

Q34596658-4B792099-DD1A-4BD3-A05F-5ED352DD56F1

Q34596658-595017BD-23EE-42A7-946C-7A14B7C65BE2

Q34596658-62FC98F8-8387-4FD6-AB9F-4E35F0F727A5

Q34596658-74BA00E2-5A7D-44F5-8274-EC9608379466

Q34596658-BC435C46-E164-4EEE-B170-3D7EC2050F61

Q34596658-DB630E36-0255-4E63-9386-C2D5D30FD4E5

P2860

Q34596658-01AD034D-DB9A-426E-98B7-68BEB2B4974A

Q34596658-0479AE92-793C-45DF-ABD4-843A97D335F9

Q34596658-13E12682-6271-447A-8C39-F434F3791063

Q34596658-169EF5D2-5C3F-4634-BF5A-85C5C7CA2DF6

Q34596658-3ED725E7-6A6B-4236-AE36-3A45CF296A9F

Q34596658-48BD04CD-019D-487F-9A69-73BB3D9D0FAF

Q34596658-5A82589F-CDED-41BD-91E2-C8D7F3A42E4F

Q34596658-60049F30-EB0A-4E08-9A39-18B01FB66B09

Q34596658-668B8842-0C7D-4DB5-80FA-633FFCEF1BAA

Q34596658-70EE802C-6B82-4295-A142-F4B0CCBBE6A4

P304

Q34596658-BE595117-6D10-4FE2-AB4A-D24F7488479A

P31

Q34596658-C8F8321A-CF4A-47FD-A9E2-C74D75A7A56A

P356

Q34596658-A62C2155-B1B5-4B8B-B045-756E0995C8EF

P407

Q34596658-9440DCA2-2625-43EA-B7EF-3EB48D32C078

P433

Q34596658-C4BC1BB5-BDA7-4287-BA05-0D146F46659B

P478

Q34596658-B96B95C1-27C6-4530-AA32-904F0B4ABEFC

P577

Q34596658-7BEFF767-EA79-4F94-AB8B-48BF75439750

P698

Q34596658-6F320602-55BA-4BA3-85FE-CC32854D3AF7

P921

Q34596658-1456D183-B8E7-4D28-8EAD-60A6623542BC

P932

Q34596658-4180D1CB-27BC-45E9-86CA-AB7D601A06A8

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment.

@en

P2093

D Morris

http://www.w3.org/2001/XMLSchema#string

E Fang

http://www.w3.org/2001/XMLSchema#string

H W Alcorn

http://www.w3.org/2001/XMLSchema#string

P Prokocimer

http://www.w3.org/2001/XMLSchema#string

R Ponnuraj

http://www.w3.org/2001/XMLSchema#string

S Flanagan

http://www.w3.org/2001/XMLSchema#string

S L Minassian

http://www.w3.org/2001/XMLSchema#string

T C Marbury

http://www.w3.org/2001/XMLSchema#string

P2860

Acute bacterial skin infections: developments since the 2005 Infectious Diseases Society of America (IDSA) guidelines

Potential role of tedizolid phosphate in the treatment of acute bacterial skin infections

Tedizolid phosphate for the management of acute bacterial skin and skin structure infections: safety summary

Prevalence of chronic kidney disease in the United States

Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America

Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections.

Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction.

Risk factors associated with the development of thrombocytopenia in patients who received linezolid therapy.

Chronic liver disease increases the risk of linezolid-related thrombocytopenia in methicillin-resistant Staphylococcus aureus-infected patients after digestive surgery.

Population pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia, in Japanese patients.

P304

6471-6476

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.03431-14

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

58

http://www.w3.org/2001/XMLSchema#string

P577

2014-08-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25136024

http://www.w3.org/2001/XMLSchema#string

P921

P932

4249404

http://www.w3.org/2001/XMLSchema#string